A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders
- 28 February 1995
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 17 (1) , 136-153
- https://doi.org/10.1016/0149-2918(95)80014-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Rank-order Stability Analysis (ROSA)Medical Decision Making, 1995
- Cumulative mean change procedure: Application to a comparative trial of venlafaxine, imipramine, and placebo in the treatment of major depressionProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1994
- The Emerging Field of Oral PharmaceuticalsThe Journal of the American Dental Association, 1994
- The Formulary Decision-Making Process in a Health Maintenance Organisation SettingPharmacoEconomics, 1994
- Meta-analysis for combining Bayesian probabilitiesMedical Hypotheses, 1991
- Avoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical CompaniesNew England Journal of Medicine, 1991
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Development of a Rating Scale for Primary Depressive IllnessBritish Journal of Social and Clinical Psychology, 1967